KPTI - Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

• Primary endpoint of phase 3 SIENDO study met in which a statistically significant improvement of progression-free survival was observed in patients treated with selinexor over placebo.
• NDA filing of selinexor as a maintenance therapy for patients with advanced or recurrent endometrial cancer expected in the 1st half of 2022.
• Full-year 2022 XPOVIO sales were guided higher of between $135 and $145 million. This 2022 estimate is higher compared to full-year 2021 sales of XPOVIO which only reached $98.4 million.
• CHMP opinion on selinexor in combination with Velcade and low-dose dexamethasone for the treatment of patients with multiple myeloma expected in 1st half of 2022.

For further details see: